La Jolla Pharmaceutical Company; | Stock Market News & Stocks to Watch from StraightStocks

DrStockPick.com Stock Report! 11/02/09, TRS, VSAT, VNO, FFIV, LJPC, GCHT

Dr. Stock Pick (November 2nd, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

**************************************************************

TriMas Corporation (Nasdaq: TRS) - a diversified manufacturer of engineered and applied products - today announced that its Monogram Aerospace Fasteners manufacturing plant in Los Angeles, California has passed the one millionth- hour mark without having a injury that resulted in a lost work day. This accomplishment represents validation of a program that was started two years ago to improve safety awareness in the manufacturing operations.

ViaSat Inc. (Nasdaq:VSAT) will host a conference call on Thursday, November 5,

...

More »

Tags for this Post:
(703) 639-1228, (866) 261-7280, broker, California, China, Company Management, Dr Stock Pick, engineered and applied products, F5 Networks Inc., GC China Turbine Corp., GC Nordic Group, Investing Lessons, La Jolla Pharmaceutical Company;, Los Angeles, Mandarin Oriental Hotel, Monogram Aerospace Fasteners manufacturing plant, Nevada, Operating Partnership, San Francisco, stock featured on our site;, Stocks to Watch, TriMas Corporation, United States, USD, ViaSat Inc., Vornado Realty L.P., Vornado Realty Trust, wind turbine manufacturer

Posted in Investing Lessons, Stocks to Watch | No Comments »

DrStockPick.com Stock Report! 11/02/09, TRS, VSAT, VNO, FFIV, LJPC, GCHT

Dr. Stock Pick (November 2nd, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Monday November 2, 2009

DrStockPick.com Stock Report!

**************************************************************

TriMas Corporation (Nasdaq: TRS) - a diversified manufacturer of engineered and applied products - today announced that its Monogram Aerospace Fasteners manufacturing plant in Los Angeles, California has passed the one millionth- hour mark without having a injury that resulted in a lost work day. This accomplishment represents validation of a program that was started two years ago to improve safety awareness in the manufacturing operations.

ViaSat Inc. (Nasdaq:VSAT) will host a conference call on Thursday, November 5,

...

More »

Tags for this Post:
(703) 639-1228, (866) 261-7280, broker, California, China, Company Management, Dr Stock Pick, engineered and applied products, F5 Networks Inc., GC China Turbine Corp., GC Nordic Group, Investing Lessons, La Jolla Pharmaceutical Company;, Los Angeles, Mandarin Oriental Hotel, Monogram Aerospace Fasteners manufacturing plant, Nevada, Operating Partnership, San Francisco, stock featured on our site;, Stocks to Watch, TriMas Corporation, United States, USD, ViaSat Inc., Vornado Realty L.P., Vornado Realty Trust, wind turbine manufacturer

Posted in Investing Lessons, Stocks to Watch | No Comments »

BioMarin Top-Line Diminishing – Analyst Blog

Zacks Market Commentaries (May 4th, 2009) Writes:

Highlights include BioMarin Pharmaceutical Inc. (BMRN) and Genzyme Corp. (GENZ).1Q09 revenue was in line with our expectation, but EPS fell shortOn April 30, 2009, BioMarin Pharmaceutical Inc. (BMRN) reported financial results for the first quarter ended March 31, 2009.Total revenue in 1Q09 came in at $74 million, up 22.5% from $60.4 million in the same quarter of 2008. Total revenue of $74 million was in line with our estimate of $74.9 million.Net product revenue in 1Q09 reached $71.9 million, up 24.8% from $57.6 million for the 1Q08. 1Q09 net product revenue was also in line with our estimate of $70.9 million. BioMarin currently markets three products.Net product revenue from Naglazyme was $39.4 million for the first quarter of 2009, an increase of 42.2 percent compared to Naglazyme net product revenue of $27.7 million for the first quarter ...

More »

Tags for this Post:
Aldurazyme;, Asia Pacific, BioMarin Pharmaceutical Inc.;, Blog, Brazil, Europe, Genzyme Corp, La Jolla Pharmaceutical Company;, lupus nephritis;, Market Commentary, Naglazyme;, proteinuria;, Riquent;, SLE;, Stocks to Watch, systemic lupus erythematosus;, Turkey, United States, USD, Western Europe, Zacks Market Commentaries

Posted in Market Commentary, Stocks to Watch | No Comments »

BioMarin Downgraded to Hold – Analyst Blog

Zacks Market Commentaries (February 20th, 2009) Writes:

We downgrade BioMarin Pharmaceutical Inc. (BMRN) shares from Buy to Hold based on worse-than-expected 4th quarter financials and the not-rosy outlook for 2009. Fourth Quarter 2008 Results Fall Short of Expectations; Outlook Not RosyBioMarin continues to deliver strong results in 4Q08, but the outlook for 2009 and beyond is not rosy. Total revenue in 4Q08 came in at $99.3 million, up 121.4% from $44.9 million in the same quarter of 2007. Fourth quarter total revenue included $15.2 million from Kuvan sales, which was not included in 4Q07. Total revenue of $99.3 million was short of our $109 million estimate. Net product revenue in 4Q08 reached $66 million, up 154.8% from $25.9 million for the 4Q07. Fourth quarter net product revenue was $8 million less than our estimate of $74 million. Naglazyme sales were $36.5 million for the 4th ...

More »